MARATTO

article · Journal of Pharmacy & Bioresources

Evaluation of haematinic activity of <i>Tapinanthus globiferus</i> (A. Rich.) van Tiegh leaf extract and fractions in phenylhydrazine-induced anaemic rats

Abstract

Anaemia is a leading cause of morbidity and mortality in both males and females of all ages. Anaemia was induced by intraperitoneal (i.p.) administration of phenylhydrazine (60 mg/kg) for a period of 3 days. Anaemic rats were allotted to five (5) groups; group I served as the negative control, group II served as the positive control received Astyfer syrup (0.15 mg/kg p.o) , groups III-V served as the test groups that received Tapinanthus globiferus methanol extract, ethyl acetate and n-hexane fractions (100, 200 and 400 mg/kg, p.o.), respectively. Packed cell volume (PCV), haemoglobin concentration (HB) and red blood cell count (RBC) were analysed as indices of anaemia at 7-day intervals for 21 days. The mean cell volume (MCV) and mean cell haemoglobin concentration (MCHC) were calculated accordingly. Leaf extract and fractions of Tapinanthus globiferus significantly (P<0.001) increased the PCV, the HB concentration and the RBC, which had been originally decreased by phenylhydrazine (P<0.001) administration within one week of treatment. The extract and fractions were compared with rats administered with the positive and vehicle-treated group. The results suggested that Tapinanthus globiferus leaves have haematinicactivities.

Research topics

  • Natural Antidiabetic Agents Studies
  • Psidium guajava Extracts and Applications
  • Bee Products Chemical Analysis

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.4314/jpb.v21i2.2

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.